| Name | Title | Contact Details |
|---|
Cydan Development is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential.
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.
Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs). With our proprietary GEODe™ platform, we are targeting the most difficult, previously undruggable receptors in the class, aiming to unlock their therapeutic utility to develop new treatments for a broad range of patients with important unmet needs.
We are harnessing the #gut brain axis & the #CNS to develop a new class of therapeutics for people with neurological diseases & disorders
Vium is the first company to create a living informatics platform for preclinical in vivo drug research.